Key Takeaways GSK's Arexvy filing seeks FDA approval for use in high-risk adults under age 50. Late-stage trial data showed Arexvy's safety matched results from previous vaccine studies. Arexvy's sales dropped 51% in 2024 amid tighter U.S. guidelines and rising vaccine competition.GSK plc (GSK) announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision is expected in the first ...